Plain-English translation of NCT03603977 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
This trial is testing a simplified HIV treatment regimen using lopinavir, ritonavir, and lamivudine โ three medications combined into one easier-to-take daily routine. Researchers want to see how well this simpler approach works for people living with HIV in real-world settings in China, and whether patients find it easier to stick with over time.
Many HIV patients struggle to take complicated medication schedules with lots of pills at different times. This trial exists to see if simplifying the regimen makes it easier for people to take their medications consistently, which is crucial for keeping the virus under control and staying healthy.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
You would take the three-medication combination by mouth twice daily for lamivudine and the other two medications. Over three years, you would visit the clinic before starting treatment, then at 12 months, 24 months, and 36 months for blood tests to check your viral load and CD4 cell count. Researchers will also monitor how well you're tolerating the medication and how consistently you're able to take it.
AI-generated summary from trial data ยท Jun 14, 2026 ยท Not medical advice
China
Sponsor
Guangzhou 8th People's Hospital
Collaborators
Guiyang Public Health Clinical Center, The Third People's Hospital of Kunming
Enrollment target
~600 participants
Started
November 2017
Primary completion
December 2025
This trial's estimated completion date has passed โ the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in September 2022.
Reach out to the team running this trial. Response times vary โ some teams are faster than others.
Central contact
Linghua Li, Doctor
Guangzhou 8th People's Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first โ no email needed to get started.